We are live on !
Find out more
SL
Siren LLC Portfolio holdings
AUM
$4.94B
Turnover
27.78%
1-Year Est. Return
244.43%
This Fund
S&P 500
This Quarter Est. Return
+74.07%
1 Year Est. Return
+244.43%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.26B
AUM Growth
+$263M
(+13%)
Cap. Flow
+$192M
Cap. Flow % of AUM
Cap. Flow %
8.48%
Top 10 Holdings %
Top 10 Hldgs %
48.54%
Holding
134
New
22
Increased
21
Reduced
22
Closed
16
Avg Time Held
Equity + Options
0.2
years
Top 10 Avg Time Held
Equity + Options
0.2
years
Top 20 Avg Time Held
Equity + Options
0.2
years
Avg Time Held Equity only
0.2
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Septerna Inc
SEPN
|
+$52.1M |
| 2 |
Bicycle Therapeutics
BCYC
|
+$39.4M |
| 3 |
Apogee Therapeutics
APGE
|
+$38.1M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
+$35.4M |
| 5 |
NewAmsterdam Pharma
NAMS
|
+$25M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Scholar Rock
SRRK
|
+$65.4M |
| 2 |
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
+$30.1M |
| 3 |
Wave Life Sciences
WVE
|
+$26.3M |
| 4 |
argenx
ARGX
|
+$16.8M |
| 5 |
Biohaven
BHVN
|
+$14.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.88% |
| 2 | Technology | 3.51% |
| 3 | Communication Services | 1.85% |
| 4 | Consumer Discretionary | 0.74% |
| 5 | Real Estate | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Revolution Medicines
RVMD
$38.1B
| $25M | 1.1% |
571,548
-182,053
| -24% | -$9.19M |
2024 Q3
1 quarter
|
|
27
Vaxcyte
PCVX
$10B
| $24.6M | 1.08% |
299,991
| – | – |
2024 Q3
1 quarter
|
|
28
Arcus Biosciences
RCUS
$2.82B
| $24M | 1.06% |
1,612,077
| – | – |
2024 Q3
1 quarter
|
|
29
Erasca
ERAS
$4.68B
| $22.2M | 0.98% |
8,857,179
| – | – |
2024 Q3
1 quarter
|
|
30
Stoke Therapeutics
STOK
$1.56B
| $22.1M | 0.97% |
+2,000,000
| New | +$24.6M |
2024 Q4
0 quarters
|
|
31
DELISTED
IGM Biosciences
IGMS
| $20.3M | 0.9% |
3,330,422
| – | – |
2024 Q3
1 quarter
|
|
32
Edgewise Therapeutics
EWTX
$4.04B
| $19.6M | 0.87% |
734,343
+330,230
| +82% | +$10.5M |
2024 Q3
1 quarter
|
|
33
Silence Therapeutics
SLN
$539M
| $19.5M | 0.86% |
2,831,770
| – | – |
2024 Q3
1 quarter
|
|
34
Cytokinetics
CYTK
$8.61B
| $18.9M | 0.84% |
402,323
-123,648
| -24% | -$6.42M |
2024 Q3
1 quarter
|
|
35
Denali Therapeutics
DNLI
$2.81B
| $17M | 0.75% |
834,028
| – | – |
2024 Q3
1 quarter
|
|
36
Korro Bio
KRRO
$125M
| $15.9M | 0.7% |
418,833
| – | – |
2024 Q3
1 quarter
|
|
37
DELISTED
Soleno Therapeutics
SLNO
| $15.8M | 0.7% |
+351,818
| New | +$18.2M |
2024 Q4
0 quarters
|
|
38
Prothena Corp
PRTA
$429M
| $15.2M | 0.67% |
1,099,840
| – | – |
2024 Q3
1 quarter
|
|
39
Solid Biosciences
SLDB
$593M
| $15M | 0.66% |
3,749,041
+1,000,000
| +36% | +$5.49M |
2024 Q3
1 quarter
|
|
40
Cullinan Oncology
CGEM
$832M
| $14.8M | 0.65% |
1,211,357
| – | – |
2024 Q3
1 quarter
|
|
41
Upstream Bio Inc
UPB
$151M
| $13.2M | 0.58% |
+800,000
| New | +$17.9M |
2024 Q4
0 quarters
|
|
42
Trevi Therapeutics
TRVI
$1.69B
| $12M | 0.53% |
+2,906,060
| New | +$9.3M |
2024 Q4
0 quarters
|
|
43
Kura Oncology
KURA
$808M
| $11.7M | 0.52% |
1,339,942
| – | – |
2024 Q3
1 quarter
|
|
44
Taysha Gene Therapies
TSHA
$1.18B
| $11.4M | 0.5% |
6,602,475
+1,722,600
| +35% | +$3.57M |
2024 Q3
1 quarter
|
|
45
Remitly
RELY
$5.11B
| $11.1M | 0.49% |
490,449
+465,449
| +1,862% | +$8.57M |
2024 Q3
1 quarter
|
|
46
Cartesian Therapeutics
RNAC
$190M
| $10.2M | 0.45% |
572,236
| – | – |
2024 Q3
1 quarter
|
|
47
Microsoft
MSFT
$3.93T
| $9.7M | 0.43% |
23,000
+1,000
| +5% | +$426K |
2024 Q3
1 quarter
|
|
48
Janux Therapeutics
JANX
$1.01B
| $9.37M | 0.41% |
+175,000
| New | +$9.26M |
2024 Q4
0 quarters
|
|
49
Seer Inc
SEER
$112M
| $9.24M | 0.41% |
4,000,000
| – | – |
2024 Q3
1 quarter
|
|
50
Ionis Pharmaceuticals
IONS
$7.14B
| $8.74M | 0.39% |
250,000
| – | – |
2024 Q3
1 quarter
|
|
Similar funds
FC
Siren LLC's Q4 2024 Portfolio in Review
As of Q4 2024, Siren LLC held 134 positions worth $2.26B, up 13% from $2B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Siren LLC deployed $192M of net new capital in Q4 2024, opening 22 new positions and adding to 21 existing holdings. Its largest new stake was Septerna Inc: 2,202,514 shares worth $50.4M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Scholar Rock, an estimated $65.4M trimmed.
- Siren LLC's largest Q4 2024 buy was Septerna Inc: 2,202,514 shares worth $50.4M.
- Siren LLC added most to NewAmsterdam Pharma in Q4 2024, an estimated $25M increase.
- Siren LLC's biggest Q4 2024 reduction was Scholar Rock, cutting an estimated $65.4M.
- Siren LLC fully exited Longboard Pharmaceuticals, Inc. Common Stock in Q4 2024, selling an estimated $30.1M.
- Siren LLC's ten largest holdings make up 49% of its $2.26B portfolio in Q4 2024.
- Siren LLC opened 22 new positions and closed 16 in Q4 2024.
- Siren LLC's portfolio value rose 13% quarter-over-quarter to $2.26B.
Based on Siren LLC's 13F filing for Q4 2024, filed 14 Feb 2025.